Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET
Company Participants
Charles Schultz - Investor Relations
Lonnel Coats - President and Chief Executive Officer
Jeffrey Wade - President and Chief Financial Officer
Craig Granowitz - Senior Vice President and Chief Medical Officer
Conference Call Participants
Jessica Fye - JP Morgan
Joseph Stringer - Needham & Company
Operator
Good morning. This is Jesse, and I will be your conference operator today. At this time, I would like to Welcome everyone to the Lexicon Pharmaceuticals, Inc’s First Quarter 2021 Earnings Conference Call. Please note all lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question and answer session. [Operator Instructions]
Thank you. I will now turn a call over to your host, Char Schultz, Executive Director, Corporate Communications and Investor Relations. Sir, you may now begin.
Charles Schultz
Thank you, Jesse. Good morning and welcome to the Lexicon Pharmaceuticals first quarter 2022 financial results conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; and Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer.
Earlier this morning, Lexicon issued a press release announcing our financial results for the first quarter of 2022, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call, along with a slide presentation is available on our website.
During this call, we will review the information provided in the release, provide a corporate update and then use the remainder of our time to answer your questions.
Before we begin, let me remind you that we will be making Forward-Looking Statements, including the statements relating to the safety, efficacy, and the therapeutic and commercial potential of sotagliflozin, LX9211 and our other drug candidates.
These statements may include characterizations of expected timing and results of clinical trials of sotagliflozin, LX9211 and our other drug candidates; and a regulatory status and market opportunity for those programs.
Call may also contain forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, launching commercialization plants for any approved products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information.
Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements. These risks include uncertainties related to the timing and outcome of our plan NDAs resubmission for sotagliflozin and heart failure, and our discussions with the FDA regarding sotagliflozin relating to heart failure and Type 1 diabetes. The success of our commercialization efforts with respect to any approved products. The timing and results of clinical trials and preclinical studies of sotagliflozin, LX9211, and our other drug candidates, our dependents upon strategic alliances and our other third party relationships. Our ability to obtain patent protections for our discoveries, limitations imposed by patents owned or controlled by third-parties and the requirements of substantial funding to conduct our planned research, development and commercialization activities.